Abstract Purpose of Review Transgender individuals are at disproportionate risk for HIV
infection, with prevalence rates highest among transgender women of color. Antiretroviral …

Purpose: Transgender women (TW) are disproportionately affected by HIV infection and
cardiovascular disease (CVD). This study evaluated whether estrogen-based gender …

Background Transgender women (TW) are disproportionately affected by both HIV and
cardiovascular disease (CVD). Objectives We aim to quantify prevalence of elevated …

Background: Feminizing hormonal therapy (FHT) and HIV potentially alter cardiovascular
disease (CVD) risk in transgender women (TW). Methods: TW were enrolled in Los Angeles …

To the Editors: Nearly a third of transgender women in the US test positive for HIV infection,
according to a meta-analysis from the Centers of Disease Control. 1 US epidemiologic …

Objectives Gender‐affirming hormonal therapies (GAHT) and HIV increase cardiovascular
risk for transgender women (TW), yet there is a paucity of data quantifying cardiometabolic …

This review examines the impact of gender affirming hormone therapy used in the
transgendered and non-binary populations on cardiovascular outcomes and surrogate …

Background The transgender population is rapidly growing in the United States and abroad.
Transgender men and women are marginalized as a result of their transgender status, with …

Objective Hormone therapy in transgender people might be associated with an increased
risk of cardiovascular disease (CVD). We aimed to investigate whether the risk of CVD is …

Gender-affirming hormone treatment generally by cross-sex hormones is an important
strategy for transgender people to achieve the physical features affirming their experienced …